Video

Dr. Mato on the Use of Biosimilars in CLL

Anthony R. Mato, MD, MSCE, discusses the use of biosimilars in chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses the use of biosimilars in chronic lymphocytic leukemia (CLL).

In July 2019, the FDA approved PF-05280586 (rituximab-pvvr; Ruxience), a biosimilar for rituximab (Rituxan), in combination with chemotherapy for patients with CD20-positive CLL.

Though Mato has not implemented biosimilars in clinical practice, he believes their use will become widespread if real-world studies demonstrate similarity between the biologic and the biosimilar. In theory, he states, these drugs should lead to similar outcomes to the biologic drug.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.
Neal D. Shore, MD, FACS
Sheldon M. Feldman, MD
Louis Crain Garrot, MD
Michel Delforge, MD, PhD
Thach-Giao Truong, MD
Aparna Parikh, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec